SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

Merck Stops Nemtabrutinib Development After Risk Review

Merck said it would stop development of experimental blood cancer drug nemtabrutinib after an independent monitoring committee concluded its benefits may not outweigh its risks.

MRK

Merck NYSE:MRK said on Tuesday it would stop development of its experimental blood cancer drug, nemtabrutinib, after a review found the treatment's benefits may not outweigh its risks.An independent monitoring committee reached that conclusion after reviewing results from a late-stage study of the…

Related stories